Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Grade 7: £32,817 - £40,322 per annum (with discretionary range to £44,045)

We are seeking a motivated Postdoctoral Researcher in T Cells with a research background in Immunology to join Professor Xin Lu’s laboratory in understanding the molecular mechanisms of tumour suppression.

You will work with the research groups of Professor Lu, Professor McMichael and Associate Professor Gillespie to study T cell response to checkpoint blockade-based therapy in Oesophageal Cancer patients. You will be responsible for managing your own academic research and administrative activities. You will collaborate in the preparation of scientific reports and journal articles and represent the research group at external meetings/seminars, either with other members of the group or alone.

It is essential that you hold PhD/DPhil (or are close to completion) in a relevant discipline, and have experience within immunology and the culture and cloning of T cells. You will have a first author publication in an international peer-reviewed journal, and have excellent communication skills.

Applications for this vacancy are to be made online and you will be required to upload a supporting statement and CV as part of your online application. Your supporting statement must explain how you meet each of the selection criteria for the post using examples of your skills and experience.

This post is offered full-time on a fixed term contract for 3 years and is funded by the Department.

Applications must be made online by 12.00 noon (UK time) on Wednesday 21st April 2021.

Similar stories

Vacancy: Executive Assistant to the Director of the Ludwig Institute for Cancer Research


Grade 6: £29,176 - £34,804 per annum (with a discretionary range to £38,017 per annum)

Drugging p53


The drug arsenic trioxide can restore the structure and function of some p53 tumour suppressor mutants, with potential as a future personalised cancer treatment strategy.